Bausch + Lomb Corporation BLCO PHARMA
Company Overview
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $5.10B (+6.5% YoY); net profit $-360.00M.
- Trailing 12 Months Year-on-year growth — revenue +9.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.38% |
| 1 Year: | 9.10% |
Stock Price Performance
| 1 Year: | +25.12% |
| 6 Months: | +2.96% |
| 3 Months: | +16.80% |
| 1 Month: | +5.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross8d ago
- RSI (14)60.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BLCO Bausch + Lomb Corporation PHARMA | 17.73 | -36.94 | $6.33B | 0.00% | 0.93% | -2.52% | 8.38% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 881.00M | 934.00M | 949.00M | 889.00M | 941.00M | 942.00M | 931.00M | 1.03B | 1.01B | 1.10B | 1.22B | 1.20B | 1.14B | 1.28B | 1.28B | 1.24B | 1.39B |
| Operating Income | 85.00M | 58.00M | 94.00M | 54.00M | 56.00M | 46.00M | -2.00M | 43.00M | 40.00M | 6.00M | 26.00M | 43.00M | -83.00M | -11.00M | 95.00M | 33.00M | 83.00M |
| Net Income | 27.00M | 44.00M | 60.00M | 20.00M | 5.00M | -18.00M | -90.00M | -32.00M | -84.00M | -167.00M | -151.00M | 4.00M | -212.00M | -62.00M | -28.00M | -71.00M | -14.00M |
| Diluted EPS | 0.08 | 0.13 | 0.17 | 0.06 | 0.01 | -0.05 | -0.26 | -0.09 | -0.24 | -0.48 | -0.43 | 0.01 | -0.60 | -0.18 | -0.08 | -0.20 | -0.04 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 3.41B | 3.77B | 3.77B | 4.15B | 4.79B | 5.10B |
| Operating Income | 260.00M | 329.00M | 207.00M | 130.00M | 162.00M | 113.00M |
| Net Income | -18.00M | 182.00M | 6.00M | -260.00M | -317.00M | -360.00M |
| Diluted EPS | -0.05 | 0.52 | 0.02 | -0.74 | -0.90 | -1.02 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 10.82B | 11.14B | 13.44B | 13.47B | 14.02B |
| Total Equity | 10.03B | 9.99B | 9.33B | 7.03B | 6.85B | 6.47B | 6.45B |
| Cash & Equivalents | - | - | 174.00M | 354.00M | 331.00M | 305.00M | 383.00M |
| Long Term Debt | - | - | 0 | 2.41B | 4.53B | 4.74B | 5.02B |
| Total Liabilities | - | - | 1.42B | 4.04B | 6.52B | 6.92B | 7.50B |
| Current Liabilities | - | - | 1.10B | 1.30B | 1.58B | 1.74B | 1.92B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 522.00M | 873.00M | 345.00M | -17.00M | 232.00M | 283.00M |
| Investing Cash Flow | -256.00M | -214.00M | -215.00M | -2.11B | -412.00M | -455.00M |
| Financing Cash Flow | -232.00M | -712.00M | 81.00M | 2.08B | 178.00M | 225.00M |
| Capital Expenditure | -253.00M | -193.00M | -175.00M | -181.00M | -291.00M | -349.00M |
| Free Cash Flow | 269.00M | 680.00M | 170.00M | -198.00M | -59.00M | -66.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | 7.6% | 8.7% | 5.5% | 3.1% | 3.4% | 2.2% |
| Net Margin % | -0.5% | 4.8% | 0.2% | -6.3% | -6.6% | -7.1% |
| ROE % | -0.2% | 2.0% | 0.1% | -3.8% | -4.9% | -5.6% |
| ROCE % | - | 3.4% | 2.1% | 1.1% | 1.4% | 0.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Icahn Carl C | 0.98% | 3.50M | $58.98M |
| 2 | Deutsche Bank AG | 0.96% | 3.42M | $57.68M |
| 3 | Oaktree Capital Management LP | 0.96% | 3.44M | $57.98M |
| 4 | Shaw D.E. & Co., Inc. | 0.93% | 3.32M | $55.99M |
| 5 | Davidson Kempner Capital Management LP | 0.88% | 3.16M | $53.23M |
| 6 | Goldentree Asset Management LP | 0.74% | 2.66M | $44.83M |
| 7 | Price (T.Rowe) Associates Inc | 0.60% | 2.16M | $36.42M |
| 8 | CASPIAN CAPITAL, LP | 0.56% | 2.00M | $33.68M |
| 9 | Glenview Capital Management, Llc | 0.54% | 1.92M | $32.32M |
| 10 | Arrowstreet Capital, Limited Partnership | 0.38% | 1.36M | $23.00M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BLCO
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOS1RqbkEydGREclNKVXJSR1pDSGwwNFNndVJ2NVU0QVl1ZjJROEpyNFRQMmU2R3FhZzdHbHNRRzRESGJTcUZZSVJfcExJLTRuMjJXLW13QnY3dlR5MHVnUVZJeGRiaWtEeDk2MllHcnRkVmpIR3lJclE0dmQ5TXE1OThiUnl1bWJTRnY2Sl…
(BLCO) Advanced Trading Insights (BLCO:CA) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPTVQza2R4RGJaZ3FXWEZZQ2hwQlZxelo0U05KbDFMSTJYXzZ0OFRDUWQwWU91SXp1Z1hmZE5tWGdrbHU3WTNYbEcxRTAzTHNpbHdLeEROSmxWZEdwUGppelZfVkZVeFYyazctUGtWX2ZlajdQV0NvVS1wcWgxMHU2dEFLY3loOFEyaWpKcX…
Bausch + Lomb (BLCO) Gains Clinical Backing As Investors Ask If The Valuation Case Holds - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQaDJZM3BCTkMxRW5LTjhIMDdjLXBMNFAzcmxtQVNpd2lxVGMzU3lldEJFc29rMkhyQ1ZOb2c4bDZfRWszSWdrV0p5NjRBQnl3Q1d2MUdwZTk0anBWNFBNOWFBRUdTQXN6V0loVjB1SUt6ZzNMR0pmVlNCRDBxdThCcjhPTWdBRzU0UUtxS2…
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today - StockStory
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQdGdCMFlIcFdxWmJncFlKajlReVBSSHBvT0tfN2UxaDROV3BwVDVMLThqcTlqN0JZWFFpSVR2RnN0el9iUEVldjlWNG5SV0hNZktmRG9vSG1LblVWdG91dkU1aG8weEVuRFJjTXRZTnFUeG8zR1k5QzRpVFJrbXdFUDJzQW1Pdmh2RS1uNG…
Every patient in the study reached mid-range vision after cataract surgery. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPd2t4Wmtibm41amxER3Q3THhrRUJRN1c1M202NmNtUmZGUkJGQ0x0V1A2UnNDUFBTNVV5b1p3R0NYbkpEUEg1N01USmpGbUVOcm9MZ3FaRFRJWXo1cWtrX1NiOGlOWFlKZXJuS2J0T1VyZmwyTzFFXzRVbWNDY25mNXV2bnJ0XzRCWkJEen…
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQcVR2TktPdTV5TFB1LXBsS0FiVklodV9kZlZsc0U1QTNyQ2dvT2lXa1NIZFlVRTZORGFDS21rNll4bDM2SC1GdWlXcm45TENtQnUwcVAyd1NwVnA0V1VmM255OXBwZUNGQmItWEMyakJsYnJxaDNoWUFud25XQzdiVldkZldsaDFkWTlqaz…
BLCO — Frequently Asked Questions
What is the current share price of Bausch + Lomb Corporation (BLCO)?
As of 2026-09-19 21:16 PDT, Bausch + Lomb Corporation (BLCO) trades at $17.73 on NYSE. Its 52-week range is $14.08 to $18.60.
What is the market capitalisation of BLCO?
Bausch + Lomb Corporation (BLCO) has a market capitalisation of $6.33B on NYSE.
What is the P/E ratio of BLCO?
BLCO trades at a trailing price-to-earnings (P/E) ratio of -36.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.98.
What is the return on equity (ROE) of BLCO?
BLCO has a return on equity (ROE) of -2.52%. Its return on capital employed (ROCE) is 0.93%.
Is BLCO a good stock to buy?
This page provides a data-driven analysis of Bausch + Lomb Corporation (BLCO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.